Press Release Archive

12.02.2020 - Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19
*/ /*-->*/ /*-->*/
  • U.K. regulator, MHRA, authorizes supply of COVID-19 mRNA vaccine for emergency supply under Regulation 174; Companies are ready to deliver the first doses to the U.K.
11.23.2020 - Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
*/ /*-->*/ /*-->*/

If approved, marstacimab has potential to be a best-in-class treatment option among novel non-factor agents –

11.20.2020 - Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
*/ /*-->*/ /*-->*/
  • In addition to today’s submission to the FDA, the companies have already initiated rolling submissions across the globe including in Australia, Canada, Europe, Japan and the U.K., and plan to submit applications immediately to other regulato
11.19.2020 - Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine
*/ /*-->*/ /*-->*/

LORBRENA treatment resulted in 72% reduction in risk of progression or death

Data also show secondary endpoint of intra-cranial response substantially improved with LORBRENA

11.18.2020 - Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
*/ /*-->*/ /*-->*/
  • Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group
  • Efficacy was
11.16.2020 - Pfizer Update On Our U.S. COVID-19 Vaccine Candidate Distribution Preparedness
  • Actions include Pfizer’s S. COVID-19 Immunization Pilot Program, that aims to help inform vaccine deployment and delivery logistics nationally
  • Pfizer has been preparing for S. distribution for a vaccine, if authorized or approved, including coordinating with the U.S. Centers for Disease Control and Prevention and Operation Warp Speed

NEW YORK, 16 November 2020 — Pfizer (NYSE: PFE) today announced the U.S.

11.16.2020 - Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it has completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.

11.12.2020 - Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg
*/ /*-->*/ /*-->*/

—Analysis of the Phase 3 ATTR-ACT clinical trial combined with its long-term extension study published in European Journal of Heart Failure—

11.11.2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Angela Hwang, Group President, Biopharmaceuticals Group, at the 2nd Annual Wolfe Research Healthcare Conference on Wednesday, November 18, 2020 at 9:50 a.m. EST.

11.11.2020 - Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens
*/ /*-->*/ /*-->*/

-Following an initial 12-week induction treatment phase, fewer patients treated with abrocitinib experienced a flare than those on placebo at any point in the trial over 40 weeks-

11.11.2020 - Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2
*/ /*-->*/ /*-->*/
  • Agreement provides a supply of 200 million doses and an option to request additional 100 million doses, with deliveries anticipated to start by the end of 2020, subject to regulatory approval
  • The vaccine supply for the EU will be produced b
11.09.2020 - Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
*/ /*-->*/ /*-->*/
  • Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
  • Analysis evaluated 94 confirmed cases of C
11.06.2020 - Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)
*/ /*-->*/ /*-->*/

Late-breaking data to be presented at ACR Convergence: the American College of Rheumatology/Association of Rheumatology Professionals’ Virtual Meeting

11.05.2020 - Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today further details regarding the proposed spin-off of its Upjohn Business and the subsequent combination of Mylan and the Upjohn Business to form Viatris Inc.

10.30.2020 - Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
*/ /*-->*/ /*-->*/

Pfizer Announces Record Date for the Proposed Transaction

10.27.2020 - FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
*/ /*-->*/ /*-->*/

-Filings based on robust abrocitinib clinical trial data demonstrating significant symptom improvement versus placebo as well as a consistent safety profile-

10.09.2020 - PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint
*/ /*-->*/ /*-->*/

NEU-ISENBURG, Germany & FRANKFURT, Germany & NEW YORK--(BUSINESS WIRE)-- The German Breast Group (GBG) and Pfizer Inc.

10.08.2020 - Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
*/ /*-->*/ /*-->*/

Results demonstrated improved treatment burden with once-weekly injection –

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.